Skip to content
Open access · CC-BY via OpenAlex

Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty

Bryon A. Tompkins, Ana Marie Landin, Victoria Florea, Makoto Natsumeda, Angela Castellanos Rieger, Wayne Balkan, Ivonne Hernandez Schulman, Joshua M. Hare

InTech eBooks · 2017 · ▲ 3 citations

Abstract

As life expectancy is projected to increase in the ensuing decades, individuals of older age continue to exceed the previous generation’s lifespan. Advancing age is associated with a reduction in physical and mental functional capacity, and chronic inflammation is a major factor contributing to this decline. A heightened inflammatory state can lead to exhaustion, weakness, weight loss, slow gate speed, and an overall decrease in activity level. These phenotypes define the onset of the disease process known as frailty. Frailty is a growing epidemic, which severely undermines a person’s ability to deal with outside stressors, and increases their rate of hospitalization, institutionalization, and mortality. Current interventions focus on preventative care by improving exercise capacity, strength, nutritional supplementation, diet, and mobility. However, a biological cure has heretofore remained elusive. Here, we introduce the novel therapeutic principle that mesenchymal stem cell (MSC) therapy may represent a safe, practical, and efficacious both the treatment and prevention of frailty in individuals of advancing age. To date, a phase I safety trial reveals an excellent safety profile and suggests that mesenchymal stem cells can ameliorate signs and symptoms of frailty. These early studies lay the groundwork for future large-scale clinical trials of this exciting and novel therapeutic concept that has the potential to expand health span in the aging population.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.5772/intechopen.69194
Canonical
link ↗
Fetched
2026-10-06 MST

Cite this

APA
Tompkins, B.A., Landin, A.M., Florea, V., Natsumeda, M., Rieger, A.C., Balkan, W., Schulman, I.H., &amp; Hare, J.M. (2017). Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty. <em>InTech eBooks</em>. https://doi.org/10.5772/intechopen.69194
Vancouver
Tompkins BA, Landin AM, Florea V, Natsumeda M, Rieger AC, Balkan W, et al. Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty. InTech eBooks. 2017. doi:10.5772/intechopen.69194.
BibTeX
@article{bryon2017Alloge, title = {Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty}, author = {Bryon A. Tompkins and Ana Marie Landin and Victoria Florea and Makoto Natsumeda and Angela Castellanos Rieger and Wayne Balkan and Ivonne Hernandez Schulman and Joshua M. Hare}, journal = {InTech eBooks}, year = {2017}, doi = {10.5772/intechopen.69194}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings